"Assuming" good data across three indicattions, and possibly more? ... $5 billion seems low based on the market potential. But realistically, it come down to financial risk/benefit. Buying RVX now based on excellent potential is a lot riskier than waiting 2-3 years for an approved drug, but then the price goes up considerably at THAT point.

So, both RVX and potential buyers have to weigh it all out, negotiate, and find that happy place, ... and the better the data, and potential market, and likelihood for FDA approval and success the more the price nudges in an investor friendly direction. 

The more potential suitors the better. Surely, under CA's, there are BP's privy to the data now, so maybe the FDA meeting is the biggest upcoming event to some? ... while for we mushroom investors it may "seem" like the AHA & cognitive meetings are the biggest events? ...

All of it is important though, because even with knowing data RIGHT NOW + positive FDA interactions, BP's will still want to gauge the reactions of academia and the scientific communities to the studies for future marketing and sales realities and tools ... after all, their Pharma reps will be going into practices and offices with those very studies detailing Cardiologists, Urologists, etc using THOSE studies to convince the doc to write RVX ..... VERY important to honor these societies, garner support, and groundswell interest from them, as they are needed to help push interest interest/need with the FDA ... and to also help sell their colleagues on the merits of the drug down the road, and developing the market along with the BP's.